USRE49579EActiveUtility

Non-peptidic GAPDH aggregation inhibitor

Assignee: UNIV OSAKA PUBLIC CORPPriority: Jun 8, 2015Filed: Jun 8, 2016Granted: Jul 18, 2023
Est. expiryJun 8, 2035(~8.9 yrs left)· nominal 20-yr term from priority
A61K 31/16A61K 31/10A61K 31/164A61P 25/16A61P 25/28C07C 323/57
45
PatentIndex Score
0
Cited by
10
References
3
Claims

Abstract

[Problem] Provided is a non-peptide compound which can be used as a GAPDH aggregation inhibitor. [Solution] Provided is a GAPDH aggregation inhibitor including as an active ingredient a compound represented by the chemical formula 1 wherein R1, R2, and R3 are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, a polysulfurized derivative thereof, or a pharmaceutically acceptable salt thereof. The present compound has a GAPDH aggregation inhibitory activity to suppress intracerebral aggregation of various proteins involved in cerebral neurodegenerative diseases, thereby contributing to improvement in various brain neurological diseases associated with aggregation of these proteins such as Alzheimer's disease, Parkinson's disease, and cerebral infarction, and prevention of advanced seriousness of these diseases.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A compound represented by any of the chemical formula 1 wherein R 1 , R 2 , and R 3  are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, the chemical formula 2 wherein R 1 , R 2 , and R 3  are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, and n is an integer of 1 or more, or the chemical formula 3 wherein R 1 , R 2 , and R 3  are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, and n is an integer of 1 or more, and or a pharmaceutically acceptable salt thereof, 
       
         
           
           
               
               
           
         
       
       
         
           
           
               
               
           
         
       
       
         
           
           
               
               
           
         
       
     
     
       2. A GAPDH aggregation inhibitor including as an active ingredient one or more compounds selected from the group consisting of a compound represented by any of the chemical formula 1 wherein R 1 , R 2 , and R 3  are each independently a hydrogen atom, a halogen atom, an aliphatic hydrocarbon group having a carbon number of from 1 to 10, the chemical formula 2 wherein R 1 , R 2 , and R 3  are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, and n is an integer of 1 or more, or the chemical formula 3 wherein R 1 , R 2 , and R 3  are each independently a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having a carbon number of from 1 to 10, and n is an integer of 1 or more, and a pharmaceutically acceptable salt thereof, 
       
         
           
           
               
               
           
         
       
       
         
           
           
               
               
           
         
       
       
         
           
           
               
               
           
         
       
     
     
       3. A pharmaceutical composition comprising the compound according to  claim 1 .

Join the waitlist — get patent alerts

Track USRE49579E — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.